Vinter-Jensen L, Jørgensen P E, Thulesen J, Poulsen S S, Nexø E
Department of Clinical Biochemistry, KH Aarhus University Hospital, Denmark.
Regul Pept. 1998 Nov 30;78(1-3):75-82. doi: 10.1016/s0167-0115(98)00126-8.
Exogenous EGF influences the levels of endogenous EGF differently in the submandibular glands (SMG) and the kidneys. The aim of the present study was to examine the time-dependent changes in levels of endogenous EGF during 1-4 weeks of EGF treatment.
Female rats were allocated into five groups receiving EGF subcutaneously (150 microg/kg/day) for 0 (controls), 1, 2, 3 and 4 weeks prior to sacrifice at an age of 12 weeks. At the end of the study period, 24-h urine samples were collected.
The weight of the SMG increased during EGF treatment (303+/-33 (controls), 359+/-37 (1 week EGF, P < 0.01), 390+/-30 (4 weeks EGF, P < 0.001) (mg mean+/-S.D.)). The EGF content of the SMG was unchanged after 1 week but threefold decreased after 4 weeks of treatment, respectively. The expression of EGF mRNA was decreased after 1 and 4 weeks as assessed with in situ hybridization. The weight of the kidneys was unchanged after 1 week and increased after 4 weeks of treatment (828+/-105 mg (controls) vs. 935+/-44 mg (4 weeks EGF, P < 0.005)). The renal content and the urinary excretion of EGF were significantly increased by 20-30% only in the group treated for 4 weeks.
EGF treatment induces a time-dependent decrease in the EGF content in the SMG most likely by reducing the biosynthesis of endogenous EGF. In contrast, the EGF content in kidneys and in urine was unchanged after 1 week and increased after prolonged treatment.
外源性表皮生长因子(EGF)对下颌下腺(SMG)和肾脏内源性EGF水平的影响有所不同。本研究旨在检测EGF治疗1 - 4周期间内源性EGF水平随时间的变化。
将雌性大鼠分为五组,在12周龄处死前分别皮下注射EGF(150微克/千克/天)0周(对照组)、1周、2周、3周和4周。在研究期结束时,收集24小时尿液样本。
EGF治疗期间下颌下腺重量增加(对照组303±33,1周EGF组359±37,P < 0.01;4周EGF组390±30,P < 0.001)(毫克,平均值±标准差)。下颌下腺的EGF含量在1周后未改变,但在治疗4周后分别下降了三倍。原位杂交检测显示,EGF mRNA表达在1周和4周后下降。肾脏重量在1周后未改变,在治疗4周后增加(对照组828±105毫克 vs. 4周EGF组935±44毫克,P < 0.005)。仅在治疗4周的组中,肾脏EGF含量和尿排泄量显著增加了20 - 30%。
EGF治疗最有可能通过减少内源性EGF的生物合成,导致下颌下腺中EGF含量随时间下降。相反,肾脏和尿液中的EGF含量在1周后未改变,在长期治疗后增加。